151 related articles for article (PubMed ID: 36363500)
1. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.
Rizzo A; Salati M; Frega G; Merz V; Caputo F; Di Federico A; Palloni A; Carloni R; Ricci AD; Gadaleta-Caldarola G; Messina C; Spallanzani A; Gelsomino F; Benatti S; Luppi G; Melisi D; Dominici M; Brandi G
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363500
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
Lowery MA; Goff LW; Keenan BP; Jordan E; Wang R; Bocobo AG; Chou JF; O'Reilly EM; Harding JJ; Kemeny N; Capanu M; Griffin AC; McGuire J; Venook AP; Abou-Alfa GK; Kelley RK
Cancer; 2019 Dec; 125(24):4426-4434. PubMed ID: 31454426
[TBL] [Abstract][Full Text] [Related]
3. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
[TBL] [Abstract][Full Text] [Related]
4. Second-line Chemotherapy Prolongs Survival in Real World Patients With Advanced Biliary Tract and Gallbladder Cancers: A Multicenter Retrospective Population-based Cohort Study.
Zaidi A; Chandna N; Narasimhan G; Moser M; Haider K; Chalchal H; Shaw J; Ahmed S
Am J Clin Oncol; 2021 Mar; 44(3):93-98. PubMed ID: 33350678
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors.
Schweitzer N; Kirstein MM; Kratzel AM; Mederacke YS; Fischer M; Manns MP; Vogel A
Liver Int; 2019 May; 39(5):914-923. PubMed ID: 30716200
[TBL] [Abstract][Full Text] [Related]
6. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
Salati M; Rizzo A; Merz V; Messina C; Francesco C; Gelsomino F; Spallanzani A; Ricci AD; Palloni A; Frega G; De Lorenzo S; Carotenuto P; Pettorelli E; Benatti S; Luppi G; Melisi D; Brandi G; Dominici M
Expert Rev Gastroenterol Hepatol; 2022 Jan; 16(1):73-79. PubMed ID: 34890512
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
[No Abstract] [Full Text] [Related]
8. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
9. Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY.
Rizzo A; Cusmai A; Giovannelli F; Acquafredda S; Rinaldi L; Misino A; Palmiotti G
Expert Rev Gastroenterol Hepatol; 2022 Mar; 16(3):273-278. PubMed ID: 35220866
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
[TBL] [Abstract][Full Text] [Related]
12. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.
Khankhel ZS; Goring S; Bobiak S; Lamy FX; Nayak D; Garside J; Reese ES; Schoenherr N
Future Oncol; 2022 Jun; 18(18):2321-2338. PubMed ID: 35387496
[TBL] [Abstract][Full Text] [Related]
13. Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
Jung K; Park J; Jung JH; Lee JC; Kim J; Hwang JH
Gut Liver; 2022 Sep; 16(5):798-805. PubMed ID: 35000934
[TBL] [Abstract][Full Text] [Related]
14. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
Okano N; Furuse J; Ueno M; Morizane C; Yamanaka T; Ojima H; Ozaka M; Sasaki M; Takahara N; Nakai Y; Kobayashi S; Morimoto M; Hosoi H; Maeno S; Nagashima F; Ikeda M; Okusaka T
Oncologist; 2021 Feb; 26(2):97-e201. PubMed ID: 33010112
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Endlicher E; Schnoy E; Troppmann M; Rogler G; Messmann H; Klebl F; Gelbmann C; Kullmann F
Digestion; 2016; 93(3):229-33. PubMed ID: 27089254
[TBL] [Abstract][Full Text] [Related]
17. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
